Finerenone selectively inhibits MR, hence obstructing pro-inflammatory signaling pathways in CKD and reducing the synthesis and secretion of pro-inflammatory mediators including IL-4 and TNF-α (Barrera-Chimal et al., 2018; Komada and Muruve, 2019). Here, NR3C2 is linked to chronic kidney disease.